| Authors: |
Huiban M; Imanova Limited, Burlington Danes Building, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK., Coello C; Imanova Limited, Burlington Danes Building, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK., Wu K; WuXi Clinical Development Service, 19th Floor, Building A, FuXing Plaza, 388 Ma Dang Road, Shanghai, 200025, China., Xu Y; GlaxoSmithKline, Neurosciences, 917 Halei Road, Zhangjiang Hi-tech Park, Pudong, Shanghai, 201203, China., Lewis Y; Imanova Limited, Burlington Danes Building, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK., Brown AP; AstraZeneca UK Limited, Melbourn Science Park, Royston, Herts, SG8 6HB, UK., Buraglio M; GlaxoSmithKline, Neurosciences, Gunnels Wood Road, Stevenage, SG1 2NY, UK., Guan C; GlaxoSmithKline, Neurosciences, 917 Halei Road, Zhangjiang Hi-tech Park, Pudong, Shanghai, 201203, China., Shabbir S; GlaxoSmithKline, Neurosciences, Gunnels Wood Road, Stevenage, SG1 2NY, UK., Fong R; UCB Biosciences Inc, PO Box 110167, Research Triangle Park, NC, 27709, USA., Passchier J; Imanova Limited, Burlington Danes Building, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK., Rabiner EA; Imanova Limited, Burlington Danes Building, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK., Lockhart A; GlaxoSmithKline, Neurosciences, Clinical Unit Cambridge, Addenbrooke's Hospital, Cambridge, CB2 0GG, UK. andrew.2.lockhart@gsk.com. |
